{"id":"NCT00156923","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults","officialTitle":"A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-10","primaryCompletion":"2007-01","completion":"2007-01","firstPosted":"2005-09-12","resultsPosted":"2010-12-03","lastUpdate":"2017-07-11"},"enrollment":108,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alcoholism"],"interventions":[{"type":"DRUG","name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL® 380 mg","Naltrexone for extended-release injectable suspension"]},{"type":"DRUG","name":"Medisorb naltrexone 190 mg","otherNames":["Naltrexone for extended-release injectable suspension"]}],"arms":[{"label":"Medisorb naltrexone 380 mg","type":"EXPERIMENTAL"},{"label":"Medisorb naltrexone 190 mg","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3, multi-center extension of Alkermes' Study ALK21-003EXT (NCT01218971) to further assess the long-term safety of repeat monthly doses of Medisorb® naltrexone (VIVITROL®).","primaryOutcome":{"measure":"Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE)","timeFrame":"Up to 3.5 years of monthly treatment","effectByArm":[{"arm":"Medisorb Naltrexone 380 mg","deltaMin":49,"sd":null},{"arm":"Medisorb Naltrexone 190 mg","deltaMin":51,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21314752"],"seeAlso":["http://apps.who.int/trialsearch/trial.aspx?trialid=NCT00156923"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":56},"commonTop":["Upper respiratory tract infection NOS","Nasopharyngitis","Arthralgia","Depression","Insomnia"]}}